Combined Chemo-Immunotherapy for Metastatic Melanoma
Author Information
Author(s): R Hoffmann, I Muller, K Neuber, S Lassmann, J Buer, M Probst, K Oevermann, A Franzke, H Kirchner, A Ganser, J Atzpodien
Primary Institution: Medizinische Hochschule Hannover
Hypothesis
The study aims to determine response rates, freedom from treatment failure, and overall survival in patients with advanced metastatic malignant melanoma treated with combined chemo-immunotherapy.
Conclusion
The combined outpatient chemo-immunotherapy regimen resulted in a 39% objective response rate and a median survival of 11 months for patients with metastatic malignant melanoma.
Supporting Evidence
- Seven patients achieved complete remissions and 20 reached partial remissions.
- Median survival was 11 months and median freedom from treatment failure was 5 months.
- Patients with low-risk features had significantly better survival outcomes.
Takeaway
Doctors treated 69 patients with a mix of chemotherapy and immunotherapy for skin cancer, and many saw their cancer get better for a while.
Methodology
Patients received up to four cycles of chemotherapy followed by outpatient immunotherapy, and were evaluated on an intention-to-treat basis.
Limitations
The study did not predict freedom from treatment failure and had a small subset of long-term responders.
Participant Demographics
{"men":45,"women":24,"median_age":56,"age_range":"20-77"}
Statistical Information
P-Value
0.0002
Confidence Interval
95% confidence interval 28-52%
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website